Kura Oncology (NASDAQ:KURA) Rating Reiterated by Wedbush

Wedbush reaffirmed their outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has a $37.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. HC Wainwright restated a buy rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, April 22nd. JMP Securities upped their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the company a market outperform rating in a report on Wednesday, January 31st. Finally, StockNews.com downgraded shares of Kura Oncology from a hold rating to a sell rating in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $28.28.

Kura Oncology Price Performance

KURA traded up $0.38 during midday trading on Friday, hitting $21.01. 770,598 shares of the company traded hands, compared to its average volume of 1,279,887. The business has a 50 day simple moving average of $20.66 and a two-hundred day simple moving average of $16.04. Kura Oncology has a 52-week low of $7.41 and a 52-week high of $24.17. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -9.65 and a beta of 0.89. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period in the previous year, the firm posted ($0.50) earnings per share. The firm’s revenue was up .0% compared to the same quarter last year. On average, equities analysts forecast that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Signaturefd LLC increased its stake in shares of Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares during the period. Pale Fire Capital SE acquired a new position in shares of Kura Oncology during the third quarter worth $92,000. E Fund Management Co. Ltd. grew its stake in shares of Kura Oncology by 12.2% during the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after purchasing an additional 1,301 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of Kura Oncology during the 3rd quarter worth about $118,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Kura Oncology by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after purchasing an additional 6,692 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.